Son y\u0131llarda, kronik lenfositik l\u00f6semi (KLL) ve k\u00fc\u00e7\u00fck lenfositik lenfoma (KLL) hastalar\u0131nda yeni ve umut vadeden bir tedavi stratejisi g\u00fcndeme geldi. Y\u00fcksek prestije sahip t\u0131p dergilerinden Blood Advances\u2019ta yay\u0131mlanan kapsaml\u0131 bir ara\u015ft\u0131rma, kolesterol d\u00fc\u015f\u00fcr\u00fcc\u00fc statin ila\u00e7lar\u0131n\u0131n, bu hastalar\u0131n sa\u011fkal\u0131m s\u00fcrelerinde anlaml\u0131 bir iyile\u015fmeye yol a\u00e7t\u0131\u011f\u0131n\u0131 ortaya koydu. D\u00fcnya genelinde yayg\u0131n olarak kullan\u0131lan statinlerin, yaln\u0131zca kardiyovask\u00fcler hastal\u0131klarla m\u00fccadelede de\u011fil, ayn\u0131 zamanda KLL ve SLL gibi yava\u015f ilerleyen hematolojik kanserlerde de tedaviye yard\u0131mc\u0131 olabilece\u011fini g\u00f6steren bu \u00e7al\u0131\u015fma, onkoloji alan\u0131nda yeni bir \u00e7\u0131\u011f\u0131r a\u00e7ma potansiyeline sahip.<\/p>\n
Kronik lenfositik l\u00f6semi, kemik ili\u011finden gelen olgun ancak fonksiyonel olmayan lenfositlerin birikmesiyle ortaya \u00e7\u0131kan en s\u0131k g\u00f6r\u00fclen eri\u015fkin l\u00f6semi t\u00fcr\u00fcd\u00fcr. K\u00fc\u00e7\u00fck lenfositik lenfoma ise ayn\u0131 k\u00f6kenden geli\u015fen ve kan yerine daha \u00e7ok lenf nodlar\u0131, dalak gibi lenfoid dokular\u0131 etkileyen bir malignitedir. Her iki hastal\u0131k da yava\u015f seyirli olmakla birlikte, standart tedavilere diren\u00e7li durumlardaki klinik tablolar hastalar i\u00e7in ciddi zorluklar yaratmaktad\u0131r. Bu nedenle tedavi yakla\u015f\u0131mlar\u0131na yeni bir soluk getirebilecek alternatif destekleyici ila\u00e7lara y\u00f6nelik ara\u015ft\u0131rmalar yo\u011funla\u015fmaktad\u0131r.<\/p>\n
Statinler, LDL kolesterol\u00fc d\u00fc\u015f\u00fcrmek amac\u0131yla re\u00e7ete edilen ve d\u00fcnya genelinde 90 milyondan fazla Amerikal\u0131 taraf\u0131ndan kullan\u0131lan ila\u00e7lard\u0131r. Lipit d\u00fc\u015f\u00fcr\u00fcc\u00fc etkilerinin yan\u0131 s\u0131ra inflamatuar yan\u0131tlar\u0131 d\u00fczenleme, h\u00fccre proliferasyonunu azaltma ve \u00e7e\u015fitli kanser h\u00fccrelerinde apoptozu tetikleme gibi \u00e7ok y\u00f6nl\u00fc etkiler g\u00f6stermektedir. \u00d6nceki g\u00f6zlemsel \u00e7al\u0131\u015fmalar, \u00e7e\u015fitli kanser t\u00fcrlerinde, \u00f6zellikle hematolojik malignitelerde statin kullan\u0131m\u0131n\u0131n sa\u011fkal\u0131m avantaj\u0131 sa\u011flayabilece\u011fini d\u00fc\u015f\u00fcnd\u00fcrm\u00fc\u015ft\u00fc. Ancak bu ara\u015ft\u0131rmalar, KLL tedavisinde devrim yaratan BTK inhibit\u00f6r\u00fc ibrutinib gibi hedefe y\u00f6nelik yeni ajanlar\u0131n yayg\u0131nla\u015fmas\u0131n\u0131n \u00f6ncesinde yap\u0131lm\u0131\u015ft\u0131r.<\/p>\n
\u00c7ok merkezli ve uluslararas\u0131 i\u015f birli\u011fiyle ger\u00e7ekle\u015ftirilen g\u00fcncel \u00e7al\u0131\u015fma, 2012-2019 y\u0131llar\u0131 aras\u0131nda d\u00f6rt farkl\u0131 klinik deneye kay\u0131tl\u0131 1.467 KLL ve SLL hastas\u0131n\u0131n verilerini inceledi. Kat\u0131l\u0131mc\u0131lar ibrutinib monoterapisi, ibrutinib kombinasyonlar\u0131 veya farkl\u0131 ibrutinib d\u0131\u015f\u0131 tedavilere randomize edildi. \u00c7al\u0131\u015fmaya ba\u015fland\u0131\u011f\u0131nda hastalar\u0131n yakla\u015f\u0131k %29\u2019u statin kullan\u0131yordu. Ortanca ya\u015f 65, erkek oran\u0131 %66, ve %92\u2019si aktif hastal\u0131k evresindeydi. Bu demografik \u00f6zellikler, \u00e7al\u0131\u015fma sonu\u00e7lar\u0131n\u0131n geni\u015f KLL\/SLL hasta pop\u00fclasyonlar\u0131na uygulanabilirli\u011fine \u0131\u015f\u0131k tutmaktad\u0131r.<\/p>\n
Ara\u015ft\u0131rma, kanser spesifik sa\u011fkal\u0131m, genel sa\u011fkal\u0131m ve progresyonsuz sa\u011fkal\u0131m gibi temel klinik sonlan\u0131mlar\u0131 analiz etti. Kanser spesifik sa\u011fkal\u0131m, tedavi ba\u015flang\u0131c\u0131ndan kanser kaynakl\u0131 \u00f6l\u00fcme kadar olan s\u00fcreyi \u00f6l\u00e7erken; genel sa\u011fkal\u0131m t\u00fcm nedenlere ba\u011fl\u0131 \u00f6l\u00fcmleri kapsar. Progresyonsuz sa\u011fkal\u0131m ise hastal\u0131\u011f\u0131n ilerlemedi\u011fi veya \u00f6l\u00fcm\u00fcn ya\u015fanmad\u0131\u011f\u0131 s\u00fcreyi ifade eder. Ayr\u0131ca statinlerin kullan\u0131m\u0131n\u0131n, ciddi ve ya\u015fam\u0131 tehdit eden yan etkilerin s\u0131kl\u0131\u011f\u0131n\u0131 art\u0131r\u0131p art\u0131rmad\u0131\u011f\u0131 da de\u011ferlendirildi.<\/p>\n
\u0130statistiksel analizler, ya\u015f, cinsiyet, fonksiyonel durum, hastal\u0131k \u015fiddeti, e\u015flik eden kardiyovask\u00fcler hastal\u0131klar, antihipertansif ila\u00e7 kullan\u0131m\u0131 ve uygulanan kanser tedavi rejimleri gibi \u00e7ok say\u0131da potansiyel kar\u0131\u015ft\u0131r\u0131c\u0131 fakt\u00f6r dikkate al\u0131narak yap\u0131ld\u0131. Bu kapsaml\u0131 \u00e7ok de\u011fi\u015fkenli modelleme, statinlerin sa\u011fkal\u0131m \u00fczerindeki ba\u011f\u0131ms\u0131z etkisini ortaya koymay\u0131 ama\u00e7lad\u0131 ve analiz sonu\u00e7lar\u0131 olduk\u00e7a dikkat \u00e7ekiciydi.<\/p>\n
Statin kullanan hasta grubunda, KLL\/SLL kaynakl\u0131 \u00f6l\u00fcm riskinde %61 azalma g\u00f6zlendi. Buna ek olarak, statin kullan\u0131m\u0131 t\u00fcm nedenlere ba\u011fl\u0131 \u00f6l\u00fcm riskini %38, hastal\u0131k progresyonu veya \u00f6l\u00fcm riskini ise %26 oran\u0131nda d\u00fc\u015f\u00fcrd\u00fc. Bu sonu\u00e7lar, statinlerin sadece kanser spesifik de\u011fil, genel sa\u011fl\u0131\u011fa da olumlu etkilerinin olabilece\u011fini g\u00f6stermektedir. Dahas\u0131, herhangi bir ciddi yan etki art\u0131\u015f\u0131 rapor edilmemi\u015ftir, bu da statinlerin hedefe y\u00f6nelik kanser tedavileri ile birlikte g\u00fcvenle kullan\u0131labilece\u011finin alt\u0131n\u0131 \u00e7izmektedir.<\/p>\n
Bununla birlikte ara\u015ft\u0131rmac\u0131lar, verilerin g\u00f6zlemsel oldu\u011funu ve klinik deneme kat\u0131l\u0131mc\u0131lar\u0131nda tedavi ve takip ko\u015fullar\u0131n\u0131n rutin klinik pratiklerden farkl\u0131l\u0131k g\u00f6sterebilece\u011fini belirterek, sonu\u00e7lar\u0131n neden-sonu\u00e7 ili\u015fkisi i\u00e7in kesin bir kan\u0131t olu\u015fturmad\u0131\u011f\u0131n\u0131 vurgulad\u0131lar. Ayr\u0131ca statinlerin t\u00fcrleri, dozlar\u0131 ve kullan\u0131m s\u00fcrelerine ili\u015fkin standartizasyon eksikli\u011fi, bu ila\u00e7lar\u0131n kanser tedavisinde nas\u0131l optimize edilmesi gerekti\u011fine dair sorular\u0131n halen yan\u0131tlanmad\u0131\u011f\u0131n\u0131 g\u00f6stermektedir.<\/p>\n
\u00c7al\u0131\u015fman\u0131n ba\u015f ara\u015ft\u0131rmac\u0131s\u0131 Prof. Dr. Ahmad Abuhelwa, statinlerin kanser ba\u015flang\u0131c\u0131, ilerlemesi ve tedavi direncinde nas\u0131l etkili olduklar\u0131n\u0131n molek\u00fcler mekanizmalar\u0131n\u0131n ayd\u0131nlat\u0131lmas\u0131 gerekti\u011fini ifade etti. H\u00fccresel d\u00fczeyde apoptoz sinyalleri, kolesterol ba\u011f\u0131ml\u0131 zar dinamikleri ve imm\u00fcn mikro\u00e7evre ile etkile\u015fimlerin laboratuvar ortam\u0131nda incelenmesi, farmakolojik hedeflerin belirlenmesinde kritik rol oynayabilir. Ayr\u0131ca, prospektif randomize klinik deneylerin planlanmas\u0131n\u0131n, statinlerin KLL ve SLL tedavisine adjuvan olarak nas\u0131l entegre edilebilece\u011fini netle\u015ftirece\u011fi belirtildi.<\/p>\n
Bu bulgular, uzun s\u00fcredir kardiyovask\u00fcler hastal\u0131klar i\u00e7in kullan\u0131lan statinlerin onkoloji alan\u0131nda yeniden de\u011ferlendirilmesi gerekti\u011fi fikrini g\u00fc\u00e7lendirdi. Statinlerin bilinen g\u00fcvenlik profili, maliyet etkinli\u011fi ve yayg\u0131n eri\u015filebilirli\u011fi, onlar\u0131 kapsaml\u0131 kanser tedavi protokollerine dahil etmek i\u00e7in ideal adaylar haline getiriyor. Metabolik d\u00fczenleyiciler ile kanser biyolojisi aras\u0131ndaki kesi\u015fim noktalar\u0131, ki\u015fiye \u00f6zel tedavi yakla\u015f\u0131mlar\u0131nda zengin bir ara\u015ft\u0131rma ve inovasyon alan\u0131 sunmaktad\u0131r.<\/p>\n
\u00dcniversite taraf\u0131ndan desteklenen bu \u00e7al\u0131\u015fman\u0131n, metabolik mod\u00fclasyon ve kanser biyolojisi aras\u0131ndaki ili\u015fkide hen\u00fcz ke\u015ffedilmemi\u015f bir\u00e7ok potansiyel oldu\u011funu g\u00f6steren g\u00fc\u00e7l\u00fc bir \u00f6rnek oldu\u011fu s\u00f6ylenebilir. Ki\u015fiselle\u015ftirilmi\u015f t\u0131bb\u0131n geli\u015fimi ile birlikte, metabolik d\u00fczenleyicilerin tedavi stratejilerine entegre edilmesi, KLL ve SLL hastalar\u0131n\u0131n sa\u011fkal\u0131m\u0131n\u0131 uzatman\u0131n yan\u0131 s\u0131ra ya\u015fam kalitelerini de art\u0131rabilir.<\/p>\n
Sonu\u00e7 olarak, modern hedefe y\u00f6nelik kanser tedavileriyle birlikte statin kullan\u0131m\u0131 aras\u0131nda g\u00f6zlenen anlaml\u0131 sa\u011fkal\u0131m art\u0131\u015flar\u0131 umut verici olmakla birlikte, klinik uygulamalarda statinlerin rutin kullan\u0131m\u0131 i\u00e7in daha ileri kontroll\u00fc klinik \u00e7al\u0131\u015fmalara ihtiya\u00e7 duyulmaktad\u0131r. Hematolojik kanserlerin global y\u00fck\u00fc her ge\u00e7en g\u00fcn artarken, geleneksel olmayan adjuvan tedavilerin ke\u015ffi hastalar i\u00e7in devrim niteli\u011finde yenilikler anlam\u0131na gelebilir. Bilim camias\u0131, statinlerin kanser tedavisindeki rol\u00fcn\u00fc kesinle\u015ftirecek gelecek \u00e7al\u0131\u015fmalar\u0131 heyecanla beklemektedir.<\/p>\n
—<\/p>\n
Ara\u015ft\u0131rma Konusu<\/strong>: Makale Ba\u015fl\u0131\u011f\u0131<\/strong>: Haberin Yay\u0131n Tarihi<\/strong>: Web References<\/strong>: Doi Referans<\/strong>: Resim Credits<\/strong>: Anahtar Kelimeler<\/strong>: Son y\u0131llarda, kronik lenfositik l\u00f6semi (KLL) ve k\u00fc\u00e7\u00fck lenfositik lenfoma (KLL) hastalar\u0131nda yeni ve umut vadeden bir tedavi stratejisi g\u00fcndeme geldi. Y\u00fcksek prestije sahip t\u0131p dergilerinden Blood Advances\u2019ta yay\u0131mlanan kapsaml\u0131 bir ara\u015ft\u0131rma, kolesterol d\u00fc\u015f\u00fcr\u00fcc\u00fc statin ila\u00e7lar\u0131n\u0131n, bu hastalar\u0131n sa\u011fkal\u0131m s\u00fcrelerinde anlaml\u0131 bir iyile\u015fmeye yol a\u00e7t\u0131\u011f\u0131n\u0131 ortaya koydu. D\u00fcnya genelinde yayg\u0131n olarak kullan\u0131lan statinlerin, yaln\u0131zca kardiyovask\u00fcler…<\/p>\n","protected":false},"author":1,"featured_media":3641,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","rank_math_title":"","rank_math_description":"","rank_math_focus_keyword":"","_wpan_schema_json_ld":"","_wpan_ai_seo_metadata":"","_wpan_ai_seo_status":"","_wpan_ai_seo_policy":"","_wpan_ai_seo_faq_block":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[28],"tags":[2644,2645,2642,2643,2641],"tmauthors":[],"class_list":{"0":"post-3640","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-kanser","8":"tag-ibrutinib-ile-kombine-kanser-tedavileri","9":"tag-kronik-lenfositik-losemi-sagkalim-oranlari","10":"tag-kucuk-lenfositik-lenfoma-tedavi-stratejileri","11":"tag-statin-ilaclarinin-hematolojik-kanserlerde-kullanimi","12":"tag-statin-tedavisi-ve-kronik-lenfositik-losemi"},"jetpack_featured_media_url":"https:\/\/haber360.com\/wp-content\/uploads\/2025\/04\/Statin-Tedavisiyle-Kan-Kanseri-Sagkalimi-Artiyor-1745419465.jpg","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts\/3640","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/comments?post=3640"}],"version-history":[{"count":0,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts\/3640\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/media\/3641"}],"wp:attachment":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/media?parent=3640"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/categories?post=3640"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/tags?post=3640"},{"taxonomy":"tmauthors","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/tmauthors?post=3640"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nKronik lenfositik l\u00f6semi ve k\u00fc\u00e7\u00fck lenfositik lenfoma hastalar\u0131nda statin ila\u00e7lar\u0131n\u0131n sa\u011fkal\u0131m sonu\u00e7lar\u0131 \u00fczerindeki etkisi.<\/p>\n
\nMakale ba\u015fl\u0131\u011f\u0131 belirtilmemi\u015ftir.<\/p>\n
\n23 Nisan 2025<\/p>\n
\n– Blood Advances journal: https:\/\/doi.org\/10.1182\/bloodadvances.2024015287
\n– Blood Advances homepage: http:\/\/www.bloodadvances.org\/
\n– Blood journals portfolio: http:\/\/www.bloodjournals.org\/
\n– American Society of Hematology: http:\/\/www.hematology.org\/<\/p>\n
\n10.1182\/bloodadvances.2024015287<\/p>\n
\nBelirtilmemi\u015ftir.<\/p>\n
\nHematoloji, Statinler, Kanser ara\u015ft\u0131rmalar\u0131, Kanser tedavisi, Kanser ve kolesterol ila\u00e7lar\u0131, Kronik lenfositik l\u00f6semi tedavisi, K\u00fc\u00e7\u00fck lenfositik lenfoma, Sa\u011fkal\u0131m art\u0131\u015f\u0131, \u0130nhibit\u00f6r tedaviler, Kanser biyolojisi, Metabolik mod\u00fclasyon, \u0130la\u00e7 yeniden kullan\u0131m\u0131.<\/p>\n","protected":false},"excerpt":{"rendered":"